Alterity Therapeutics (ATHE) Competitors $4.70 +0.24 (+5.26%) As of 01:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. THTX, BDTX, ALTS, LYEL, IKT, SKYE, GALT, GLSI, RAPT, and NMRAShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), Lyell Immunopharma (LYEL), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), Rapt Therapeutics (RAPT), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Theratechnologies Black Diamond Therapeutics ALT5 Sigma Lyell Immunopharma Inhibikase Therapeutics Skye Bioscience Galectin Therapeutics Greenwich LifeSciences Rapt Therapeutics Neumora Therapeutics Theratechnologies (NASDAQ:THTX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership. Which has more risk and volatility, THTX or ATHE? Theratechnologies has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Do institutionals & insiders hold more shares of THTX or ATHE? 2.1% of Alterity Therapeutics shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer THTX or ATHE? Alterity Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 155.05%. Given Alterity Therapeutics' higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is THTX or ATHE more profitable? Alterity Therapeutics has a net margin of 0.00% compared to Theratechnologies' net margin of -10.85%. Company Net Margins Return on Equity Return on Assets Theratechnologies-10.85% N/A -9.83% Alterity Therapeutics N/A N/A N/A Which has preferable earnings and valuation, THTX or ATHE? Theratechnologies has higher revenue and earnings than Alterity Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$84.38M1.71-$8.31M-$0.19-16.55Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the media refer more to THTX or ATHE? In the previous week, Alterity Therapeutics had 1 more articles in the media than Theratechnologies. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Theratechnologies. Alterity Therapeutics' average media sentiment score of 0.93 beat Theratechnologies' score of 0.05 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Theratechnologies Neutral Alterity Therapeutics Positive SummaryAlterity Therapeutics beats Theratechnologies on 9 of the 13 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.73M$2.92B$5.56B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.3528.6119.64Price / SalesN/A304.32437.49188.30Price / CashN/A43.1536.0257.93Price / Book4.527.718.185.63Net Income-$12.54M-$55.11M$3.23B$257.73M7 Day Performance20.33%0.68%-0.25%0.07%1 Month Performance6.69%8.22%5.40%8.32%1 Year PerformanceN/A-2.64%26.35%13.78% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.1582 of 5 stars$4.71+5.3%$12.00+155.0%+122.4%$41.73MN/A0.0010Gap DownTHTXTheratechnologiesN/A$3.17-0.9%N/A+103.9%$147.14M$85.87M-39.63140Earnings ReportHigh Trading VolumeBDTXBlack Diamond Therapeutics2.8619 of 5 stars$2.50-3.1%$12.80+412.0%-51.0%$146.71MN/A41.6790News CoveragePositive NewsALTSALT5 Sigma0.1337 of 5 stars$7.54-8.4%N/AN/A$143.65M$12.53M0.00170LYELLyell Immunopharma3.2463 of 5 stars$9.15-5.6%$15.00+63.9%-73.5%$143.49M$60K-0.37270News CoverageIKTInhibikase Therapeutics1.4904 of 5 stars$1.93+2.1%$6.50+236.8%+20.8%$143.48MN/A-0.726SKYESkye Bioscience2.1426 of 5 stars$4.39-4.8%$16.60+278.1%-40.6%$142.80MN/A-5.3511GALTGalectin Therapeutics2.2471 of 5 stars$2.15-1.4%$6.00+179.1%+17.6%$137.98MN/A-2.999Gap UpGLSIGreenwich LifeSciences2.1494 of 5 stars$10.07+0.4%$39.00+287.3%-35.6%$134.08MN/A-7.993RAPTRapt Therapeutics4.3508 of 5 stars$8.16+1.4%$24.00+194.1%-62.9%$133.12M$1.53M-0.4280Trending NewsAnalyst RevisionNMRANeumora Therapeutics2.7245 of 5 stars$0.90+9.0%$7.50+737.7%-87.5%$132.89MN/A-0.56108News CoveragePositive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies THTX Competitors BDTX Competitors ALTS Competitors LYEL Competitors IKT Competitors SKYE Competitors GALT Competitors GLSI Competitors RAPT Competitors NMRA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATHE Stock Alerts